[PDF][PDF] Treatment of renal cell carcinoma: current status and future directions
Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma
B Bhindi, EJ Abel, L Albiges, K Bensalah, SA Boorjian… - European urology, 2019 - Elsevier
Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma …
Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …
Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study
Purpose The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) has become unclear since the introduction of targeted therapies (TT). We sought to …
(mRCC) has become unclear since the introduction of targeted therapies (TT). We sought to …
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the …
Background The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective To …
carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective To …
Landmarks in the diagnosis and treatment of renal cell carcinoma
JR Bhatt, A Finelli - Nature Reviews Urology, 2014 - nature.com
The most common renal cancer is renal cell carcinoma (RCC), which arises from the renal
parenchyma. The global incidence of RCC has increased over the past two decades by 2 …
parenchyma. The global incidence of RCC has increased over the past two decades by 2 …